Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 20,551 shares at $16.28 ($335K) on 2023-06-06, disclosed to the SEC on 2023-06-08.
Scheduled sale ($335k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.28 | 10,268 | $167K | 50.0% |
| 2 | $16.28 | 10,268 | $167K | 50.0% |
| 3 | $16.98 | 15 | $255 | 0.1% |
| Total | $16.28 avg | 20,551 | $335K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |